Media stories about Chiasma (NASDAQ:CHMA) have trended somewhat positive this week, Accern Sentiment reports. The research firm identifies negative and positive news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Chiasma earned a coverage optimism score of 0.00 on Accern’s scale. Accern also assigned media stories about the biotechnology company an impact score of 47.3193893800214 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Chiasma (NASDAQ CHMA) traded up $0.07 during trading on Tuesday, hitting $2.10. The stock had a trading volume of 37,600 shares, compared to its average volume of 89,226. Chiasma has a twelve month low of $1.25 and a twelve month high of $2.95.
Separately, ValuEngine raised Chiasma from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st.
COPYRIGHT VIOLATION NOTICE: This piece of content was published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this piece of content on another site, it was illegally copied and republished in violation of U.S. and international trademark & copyright laws. The original version of this piece of content can be accessed at https://sportsperspectives.com/2017/11/14/chiasma-chma-receives-daily-coverage-optimism-score-of-0-00.html.
In related news, Director Scott Minick acquired 15,000 shares of the firm’s stock in a transaction on Wednesday, September 20th. The shares were bought at an average cost of $2.38 per share, with a total value of $35,700.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders own 3.80% of the company’s stock.
Chiasma, Inc is a biopharmaceutical company. The Company is engaged in developing and commercializing oral forms of therapies that are available only by injection. Using its Transient Permeability Enhancer (TPE) technology platform, the Company is developing oral therapies. The Company has completed a Phase III clinical trial of its TPE platform-based product candidate, oral octreotide capsules (trade named as MYCAPSSA) for the treatment of acromegaly, a condition that results in the body’s production of excess growth hormone.
Receive News & Ratings for Chiasma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chiasma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.